Insider Selling: Relay Therapeutics (NASDAQ:RLAY) Insider Sells $11,136.87 in Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) insider Peter Rahmer sold 753 shares of the company’s stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $14.79, for a total value of $11,136.87. Following the transaction, the insider directly owned 275,857 shares of the company’s stock, valued at $4,079,925.03. This represents a 0.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Relay Therapeutics Price Performance

RLAY stock opened at $12.72 on Friday. The stock has a market capitalization of $2.43 billion, a P/E ratio of -7.85 and a beta of 1.74. The business has a 50-day moving average of $11.87 and a 200-day moving average of $9.15. Relay Therapeutics, Inc. has a fifty-two week low of $2.67 and a fifty-two week high of $17.32.

Relay Therapeutics (NASDAQ:RLAY) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.06. The firm had revenue of $7.00 million for the quarter, compared to analyst estimates of $4.34 million. Equities analysts expect that Relay Therapeutics, Inc. will post -1.51 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on RLAY. JonesTrading began coverage on Relay Therapeutics in a report on Tuesday, April 14th. They set a “hold” rating and a $18.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a report on Wednesday, April 8th. Citizens Jmp upped their target price on Relay Therapeutics from $17.00 to $19.00 and gave the stock a “market outperform” rating in a report on Tuesday, April 28th. HC Wainwright upped their target price on Relay Therapeutics from $19.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Oppenheimer upped their target price on Relay Therapeutics from $14.00 to $18.00 and gave the stock an “outperform” rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Relay Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $20.56.

Institutional Trading of Relay Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Commodore Capital LP raised its holdings in Relay Therapeutics by 27.3% during the third quarter. Commodore Capital LP now owns 17,000,000 shares of the company’s stock worth $88,740,000 after acquiring an additional 3,650,000 shares in the last quarter. Casdin Capital LLC raised its stake in Relay Therapeutics by 14.7% in the fourth quarter. Casdin Capital LLC now owns 13,003,574 shares of the company’s stock valued at $110,010,000 after buying an additional 1,662,193 shares during the period. Vanguard Group Inc. raised its stake in Relay Therapeutics by 3.1% in the fourth quarter. Vanguard Group Inc. now owns 9,691,445 shares of the company’s stock valued at $81,990,000 after buying an additional 295,701 shares during the period. Bellevue Group AG raised its stake in Relay Therapeutics by 1.4% in the third quarter. Bellevue Group AG now owns 8,345,610 shares of the company’s stock valued at $43,564,000 after buying an additional 114,740 shares during the period. Finally, State Street Corp raised its stake in Relay Therapeutics by 26.8% in the fourth quarter. State Street Corp now owns 6,426,111 shares of the company’s stock valued at $54,365,000 after buying an additional 1,360,121 shares during the period. Institutional investors own 96.98% of the company’s stock.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.